Hi, what are you looking for?
Jewish Business News
Search results for "TEVA"
Business
As Israeli pharmaceutical giant Teva pushes ahead with a $40-billion dollar hostile bid for US generic drugmaker Mylan, Brent Saunders, CEO of...
Business
Teva declined the chance because it does not operate in the store-brand OTC market, Perrigo's main activity.
Business
Reuters Exclusive: Generics drugmaker Mylan NV (MYL.O), which is in the middle of a three-way takeover battle, has said it is unwilling to...
Business
John Paulson's hedge fund has increased its holdings in Mylan NV to 4.5%.
Leadership & A-List
The Teva shareholder and digital printing pioneer thinks Teva should be investing in innovation, not cheap commodity drugs.
Business
[FULL LETTER] After Mylan Responded aggressively to Teva's bid, Erez Vigodman says in an open letter to Robert Coury: Shareholders won't benefit from Mud...
Business
Julius Baer analyst Lilian Montero insists it's illogical for Mylan to remain independent.
Court
Tamir Capital is invested in Proneuron, which successfully sued Teva for abuse of a license for its product.
Business
Board concludes that approach grossly undervalues Mylan, includes Teva stock, and would expose Mylan to a problematic culture and leadership with poor record of...
Business
Teva CEO Erez Vigodman bypasses Mylan's board and appeals directly to its shareholders.